LOS ANGELES, CA -- (Marketwired) -- 06/16/14 -- Verde Science, Inc. (OTCBB: VRCI) Board of Directors of is pleased to announce the appointment of Mr. Ken Berscht to the position of CEO. The Board of Directors welcomes Ken with great enthusiasm and believe they have found a dynamic and engaging leader to guide Verde through the maze of regulatory and financial hurdles in this nascent business opportunity. Mr. Berscht stated, "I am honored by the opportunity to lead Verde Science as the medical marijuana space is undergoing such a fundamental transfiguration."
Mr. Harp Sangha the outgoing CEO and creator of Verde's current vision shared, "Since the inception of Verde's current path towards being a dominant force in the North American horticultural and marijuana industry, I have been building a team of experienced management from the medical marijuana industry and public company sector management. Ken is the next cog in that wheel to complete the current team. I am can now step down as CEO with confidence and assume a less day to day role in the company as a member of the board of directors."
Mr. Ken Berscht is a graduate of the University of Western Ontario Business School where he received an honors degree in Business with a major in advertising and marketing. Earlier in his career he was qualified as an International Financial Advisor in England, and a member of the Society of Mining, Metallurgy and Exploration.
He has been a member of the Investment Dealers Association in Canada and as a principle member with NASDAQ and the NYSE in the USA.
During his career he has been a senior investment advisor with Yorkton Securities and Canaccord Capital. He has extensive experience in all aspects of the financial community with clients from Europe and Asia in addition to an extensive North American network.
In Taiwan Mr. Berscht had a ground breaking business and attracted over 3,000 clients to the North American market making him one of the largest brokers in Canada at the time.
Mr. Berscht was the vice president of Enerplus International, a division of one of Canada's largest income trusts. He spent considerable time in Europe and the Cayman Islands. In the Caymans, he also managed an oil and gas fund for 10 years and is qualified there as a mutual fund administrator.
Throughout his career Mr. Berscht has always been on the leading edge of industry trends. He was one of the pioneers launching the JCP and CPC financing. He has always been a pioneer the market, trailblazing new opportunities as they present themselves.
About Verde Science
Verde Science plans to take an all-encompassing, integrated public health approach to medical marijuana with a focus on becoming the leader in providing services to legal, licensed cannabis cultivators and dispensaries and their patient community. Verde's focus, in collaboration with its partners, is on deploying an advanced array of technical services to foster an integrated health care model in legal jurisdictions in North America.
The Company provides a variety of products and services to its clients by using best practices to ensure the best quality of product, produced with focus on cost control and legal compliance. Verde Science is meticulous, measured and diligent with an absolute focus on compliance while offering growers and their patient community unsurpassed, fully integrated, holistic health care products and programs.
http://verdescienceinc.com is one of the initial corporate players in the medical marijuana industry providing sophistication, controls, standards and innovation. The company has and will continue to assemble a highly experienced team that will deploy state-of-the-art technology and a superior methodology to enter and take meaningful market share that can be repeated and expanded as more and more jurisdictions adopt legal use of cannabis products to address health care issues.
Safe Harbor Statements
Certain information contained in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates", "intends" or "believes", or that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur", or "be achieved". Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.